Adobe Stock
Dalal Street had its eyes glued to Apollo Hospitals share price today. The stock shot up over 6 per cent, climbing to a new 52-week high of Rs 7,717.
The trigger? A quarterly report that packed a punch and whispers of a value-unlocking demerger. In short, the bulls came charging.
Apollo Hospitals’ Q1 scorecard
| Metric | Q1 FY26 | Q1 FY25 | YoY change |
|---|---|---|---|
| Net profit (Rs crore) | 433 | 305 | 42 per cent |
| Revenue (Rs crore) | 5,842 | 5,086 | 15 per cent |
| EBITDA (Rs crore) | 852 | 675 | 26 per cent |
| EBITDA margin (%) | 14.6 | 13.3 | 130 bps |
Strong patient volumes, higher occupancy rates, and pharmacy growth all played their part. Margins inched up, too, the kind of operating leverage the street likes to see.
Why the rally matters
- Strong growth and margin gains: Signals pricing power and operational efficiency.
- Demerger in sight: Apollo Healthco’s spin-off could unlock hidden value.
- Macro tailwinds: Softer inflation keeps the risk-on mood alive.
But here’s the catch: At over 66 times earnings, the stock is priced for perfection. Any miss in execution or a wobble in sentiment could make the fall sharper than the rise.
What does Apollo Hospitals do?
Apollo Hospitals Enterprise Ltd isn’t just a hospital chain; it’s a healthcare empire. From world-class hospitals to India’s largest pharmacy network, diagnostics, telehealth and its Apollo 24/7 platform, the group is stitched into almost every part of the country’s healthcare fabric.
Our take
Today’s move wasn’t a fluke. Apollo Hospitals’ Q1 print gave the bulls fresh ammo, and the demerger chatter is adding sparkle. For long-term investors eyeing India’s healthcare growth story, Apollo remains a heavyweight. Just remember — at these valuations, there’s little room for error.
Disclaimer: This article was crafted with the aid of artificial intelligence and meticulously reviewed and edited by our human experts to ensure accuracy and provide valuable insights. It's intended for informational purposes only. We encourage you to conduct your own thorough research before making any investment decisions.
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]






